Cancer Research Targets Metabolism
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, B.
Right arrow Articles by Thor, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, B.
Right arrow Articles by Thor, A.
[Cancer Research 65, 879-886, February 1, 2005]
© 2005 American Association for Cancer Research

Cell and Tumor Biology

Low-Dose Dietary Phytoestrogen Abrogates Tamoxifen-Associated Mammary Tumor Prevention

Bolin Liu1, Susan Edgerton1, Xiaohe Yang1, Aeree Kim1, Dalia Ordonez-Ercan1, Terza Mason1, Kathy Alvarez1, Christine McKimmey1, Naxin Liu2 and Ann Thor1

1 Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma and 2 Evanston Northwestern Healthcare Research Institute, Evanston, Illinois

Requests for reprints: Ann Thor, Department of Pathology, University of Oklahoma Health Sciences Center, 940 Stanton L Young Boulevard, BMSB 451, Oklahoma City, OK 73104. Phone: 405-271-2422; Fax: 405-271-2568; E-mail: ann-thor{at}ouhsc.edu.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Wild-type erbB-2/neu transgenic mice were used to study the interactions between tamoxifen and dietary phytoestrogens (or isoflavones) by dose and form in vivo. Mice were randomized to one of four dietary formulas and implanted with an 8-week continuous-release tamoxifen or placebo pellet at 8 weeks of age. In placebo-treated mice, soy meal diet (but not diets supplemented with low-dose or high-dose isoflavones or a casein diet) resulted in prolongation of tumor latency. In tamoxifen-treated mice fed the soy meal, casein, or high-dose isoflavone enriched diets, the majority (>80%) showed no tumor formation by 60 weeks of age. Of the mice that developed tumors, latency was significantly prolonged. In tamoxifen-treated mice fed the low-dose isoflavone enriched diet, a much higher rate of mammary tumor development (>50%; P < 0.002) and a shorter tumor latency were observed. In vitro studies of human and mouse mammary tumor cell lines confirm that low doses of genistein, co-administered with tamoxifen, promote cell proliferation. This is in contrast to tamoxifen alone or tamoxifen with higher doses of genistein that are growth inhibitory. In summary, low-dose dietary isoflavones abrogated tamoxifen-associated mammary tumor prevention in vivo. These interactions are supported by in vitro data from human and mouse mammary tumor cell lines. These dose-associated interactions likely have relevance to the human use of tamoxifen for prevention or treatment of breast cancer.

Key Words: Breast Cancer • Estrogen • Transgenic Mouse • erbB-2


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Higher doses and longer duration of estrogen exposure are associated with increased incidence of breast cancer in population-based studies (1, 2). Estrogen is particularly deleterious in women with an increased risk due to a strong family history of the disease (3). Estrogen promotes mammary epithelial cell growth via classic mechanisms and nonclassic pathways, described in more detail below and in Discussion. Interactions between dietary or supplemental plant-derived estrogens (phytoestrogens, also known as isoflavones) and estrogen signaling, mammary tumorigenesis, or exogenous estrogens/antiestrogens are not well studied.

The biological and reproductive processes that govern mammary gland biology and cancer risk in vivo are highly complex. Estrogen-associated signaling pathways include both the classic (ligand-stimulated) and nonclassic (ligand-independent) pathways; reviewed in detail elsewhere (4). Benign mammary epithelial cells and most mammary cancers express the estrogen receptor (ER), a class I nuclear receptor that exists in both {alpha} and ß forms (5). Recent evidence suggests that the {alpha} form is most prevalent in human breast cancers and is associated with low-grade lesions and endocrine sensitivity (6). In breast cancer patients, ER expression has been used as a marker of intact estrogenic signaling, a more favorable prognosis, and probable responsiveness to antiestrogenic agents (4). Agents that modify ER-associated signaling are typically selective estrogen receptor modulators (SERM; ref. 4). SERMs exhibit mixed antagonist-agonist tissue-specific activities, modulate ER expression, may alter ER conformation and ligand binding, and change the expression or binding of coregulator proteins (7, 8). Antiestrogenic strategies have been remarkably efficacious for breast cancer treatment and prevention. Of these, tamoxifen is the most widely prescribed SERM worldwide (8, 9). Factors that might interfere with the efficacy of tamoxifen, by either direct or indirect mechanisms, may modify its efficacy for breast cancer treatment or prevention (10).

Plant-derived phytoestrogens (or isoflavones) are also SERMs because they show mixed estrogen angonist-antagonist activities. Phytoestrogens are found in particularly high doses in soy beans, which contain the isoflavones 4"5,7-trihydroxyisoflavone (genistein),4',7-dihydroxyisoflavone (daidzein), and their respective ß-glycosides (11). Phytoestrogen (or soy) consumption has been associated with reduced risk of breast cancer (12, 13), improved cardiovascular health, and increase in bone density at higher levels. The type and combination of individual isoflavones, plant source, as well as extraction method, dose, and consistency of use are likely modifiers of these benefits (12, 14, 15).

Soy derivatives (or phytoestrogens) are increasingly used in cosmetics as an unregulated drug supplement, as a food additive to enhance dietary protein, or as a food texture modifier. Intentional dietary enrichment or supplement use is common in women seeking an alternative to hormonal replacement therapy and a preventive agent against breast cancer, osteoporosis, or cardiovascular disease (16–18). The stage of life during which isoflavones are consumed and the dose and form that are ingested may critically influence its biological effects (19, 20). Even modest amounts (≤100 mg) of isolated isoflavones may exert biological effects in vivo (16, 21).

Dietary phytoestrogens may influence signal transduction of both the steroid receptor and the receptor tyrosine kinase (erbB-1, erbB-2, erbB-3, and erbB-4) signaling pathways as well as other biological phenomena. ErbB-2 encodes a transmembrane glycoprotein, p185, with intrinsic tyrosine kinase activity (22). p185 is commonly overexpressed in association with gene amplification in 30% of primary invasive breast cancers. Cell lineage determines the expression of both receptor tyrosine kinase receptors and ligand binding partners, which in turn determines the combinatorial effect and pathway signaling, apoptosis, cell proliferation, angiogenesis, modulation of transcriptional regulators, and signal transduction (23).

We have previously reported that brief exposure to 17ß-estradiol (E2; at 8-16 weeks of age) was associated with mammary tumor induction at a younger age in the wt-erbB-2 transgenic mouse model. E2 exposure resulted in mammary tumors that were more frequently invasive, higher grade, and multifocal (24). The E2-associated phenotypic aggression seemed stable in derived mammary cell lineages as mammary tumor-derived cell lines also showed more rapid growth and clonogenicity in soft agar (25). The transgenic mice exposed to short-term tamoxifen (also at an early age, 8-16 weeks) generally failed to develop mammary tumors by 60 weeks of age (tumor prevention, >80%). Similar biological responses to estrogenic hormones have been observed in women, indicating important similarities between the wt-erbB-2 model and human breast cancer. We have also reported phenotypic heterogeneity in this model system with approximately 10% of tumors showing unique histologic growth patterns (26). Again, this is reminiscent of what is observed in human breast cancer. Finally, both this mouse model and human breast cancer often show erbB-2, p53, and epidermal growth factor receptor abnormalities. We therefore believe that the wt-erbB-2 mouse model has biological relevance to human breast cancer.

In addition to studying the influence of estrogen, we have evaluated the effect of diet-based estrogenic agents using both open and closed commercial diets. In particular, we have focused on interactions between exogenous and dietary components. For example, we have reported that mice fed the soy meal diet developed mammary tumors at a later age than casein-fed animals treated with E2 or placebo, whereas no differences were observed by diet for the tamoxifen-treated mice (24).

As an extension of those studies and the conflicting literature regarding the benefits of phytoestrogens, we hypothesized that various doses or forms of dietary phytoestrogens may alter mammary gland development, tumorigenesis, or the preventive effects of tamoxifen. To explore this hypothesis, we extended our in vivo studies of the genetically at risk transgenic mouse and confirmed critical observations using both human and mouse mammary tumor cell lines.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Cells and Cell Culture. The human breast cancer cell line MCF-7 was obtained from the American Type Culture Collection (Rockville, MD) and maintained in DMEM and Ham's F-12 medium (1:1, v/v; Invitrogen Corp., Grand Island, NY) supplemented with 10% fetal bovine serum (Invitrogen). This cell line was cultured in a 37°C humidified atmosphere containing 95% air and 5% CO2 and was split twice a week.

Mice. Animal care was provided in accordance with institutional guidelines in our mouse facility approved by the Association for Assessment and Accreditation of Laboratory Animal Care. Protocols and experiments were reviewed and approved by our Institutional Animal Care and Use Committee. Three-hundred eighty-seven virgin female FVB-TgN(MMTV-neu) transgenic mice (wt-erbB-2) were obtained from Jackson Labs (Bar Harbor, ME) at 4 to 5 weeks of age. Mice were placed on one of four different diets on arrival. The diets contained various levels of isoflavones, derived from soy meal or organically extracted genistein and daidzein. These included three separate soy diets: Purina 5001 (a soy meal-based diet containing ~500 µg/g isoflavones; Ralston Purina Co., St. Louis, MO; n = 78), RD D11247 (an isolated isoflavone diet containing ~211 µg/g isoflavones, Research Diets, Inc., New Brunswick, NJ; n = 76), RD D2061301 (an isolated isoflavone diet containing ~500 µg/g isoflavones, Research Diets; n = 58; ref. 27). The remaining mice were placed on casein (milk protein-based) diets, Purina 5K96 (0 µg/g isoflavones; Ralston Purina; n = 99) or RD D11243 (0 µg/g isoflavones, Research Diets; n = 76), which were matched controls to Purina 5001 or RD D11247, respectively. A summary of the dietary composition of these diets is shown (Table 1).


View this table:
[in this window]
[in a new window]

  		Table 1. Composition of mouse diets

 
Treatment Groups. At 8 weeks of age, mice were implanted with a single 60-day constant release pellet in the lateral neck. A placebo pellet was implanted in 184 animals. A single 5.0 mg tamoxifen pellet was implanted in 203 mice. All pellets were obtained from Innovative Research of America (Sarasota, FL). Mice were checked twice weekly for tumor formation. Tumor latency was calculated from the date of first palpable tumor. Necropsies were done on each animal and included removal with gross and microscopic examination of mammary glands, examination of lungs (gross and microscopic), and gross examination of other organs except brain and spinal cord. A summary of the mouse treatment randomization, including the number of mice in each group, etc., is provided in a tabular form for convenience (Table 2).


View this table:
[in this window]
[in a new window]

  		Table 2. Numbers of mice used for diet and treatment experiments

 
The histologic examination of all palpable or visible tumors was done to confirm tumorigenesis and evaluate tumor histology. The histologic patterns and heterogeneity of these and other mammary tumors have been reported elsewhere (26). Benign mammary glands were also harvested for studies of gland development and gene expression that are ongoing.

Western Blot Analysis. Protein expression levels were determined by Western blot analysis as previously described (28). Briefly, cells were lysed in a buffer containing 50 mmol/L Tris, pH 7.4, 50 mmol/L NaCl, 0.5% NP40, 50 mmol/L NaF, 1 mmol/L Na3VO4, 1 mmol/L phenylmethylsulfonyl fluoride, 25 µg/mL leupeptin, and 25 µg/mL aprotinin. The lysates were centrifuged at full speed in a microcentrifuge for 15 minutes and the supernatants were collected for protein concentration determination, SDS-PAGE, and Western blot analysis with specific antibodies as described in the figure legends.

Establishment of Novel, Mouse Mammary Tumor Cell Lines. Mammary tumors were obtained from the transgenic mice by surgical removal, immediately following euthanasia according to the protocol approved by our Institutional Animal Care and Use Committee. These methods have been previously described in detail (25). In brief, solid tumor tissue was transferred into a tissue culture dish containing PBS. After physical removal of mammary fat and connective tissues, tumors were minced into small pieces and treated with 0.25% trypsin-EDTA (Invitrogen) at 37°C for 30 minutes. Cells were subsequently centrifuged at 1200 rpm for 5 minutes. After discarding the supernatant, cells were suspended in DMEM/F12 medium supplemented with 10% fetal bovine serum and 1% antibiotics and antimycotics (Invitrogen). These mammary tumor cells (~1.0 x 106 cells/plate) were seeded in tissue culture dishes and kept in a 37°C humidified atmosphere containing 95% air and 5% CO2. The media were changed twice a week to maintain cells in culture. Each line was passaged ~20 times before stability was assumed.

RNA Extraction, cDNA Synthesis, and Reverse Transcription-PCR Analysis. Total RNA was extracted using a modified chloroform/phenol procedure (TRIZOL, Invitrogen). First-strand cDNA was generated using reverse transcriptase (Roche Diagnostics Corp., Indianapolis, IN) following the protocol of the manufacturer, and subsequently amplified by PCR using the Expand High Fidelity PCR System (Roche) and the following primer sets: ER{alpha} forward primer, 5'-CGG TCT ACG GCC AGT CGG GCA TC-3', and reverse primer, 5'-CGC TGG GCT CGT TCT CCA GGT AGT A-3'; ß-actin forward primer, 5'-GCA CCA CAC CTT CTA CAA TGA GC-3', and reverse primer, 5'-GAC GTA GCA CAG CTT CTC CTT AAT G-3'.

Cell Proliferation Assay. A CellTiter96 AQ nonradioactive cell proliferation kit (Promega Corp., Madison, WI) was used to determine the number of viable cells in the absence or presence of tamoxifen and/or genistein (Sigma Chemical Co., St. Louis, MO). In brief, cells were plated onto 96-well plates. Twenty-four hours later, cells were grown in 100 µL fresh medium as control, or 100 µL fresh medium containing tamoxifen or genistein alone, or 100 µL fresh medium containing the combinations of different doses of tamoxifen and genistein. Cells were incubated at 37°C in a 5% CO2 atmosphere for 72 hours and cell proliferation assay was done to measure the conversion of" 3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) into a water-soluble formazan by dehydrogenase enzymes in living cells. The absorbance of formazan at 490 nmol/L was recorded by a microplate reader. The percentages of cells surviving from each group relative to controls, defined as 100% survival, were determined by reduction of MTS. All proliferation data shown are the means of at least three independent experiments.

Statistical Methods. Time to first tumor and average time to tumor development were tested using ANOVA. All significant statistics were confirmed using either the Kruskal-Wallis or the Mann-Whitney test. Tumor-free intervals (tumor latency) for survival curves were calculated using the Cox proportional hazards model and differences were tested using the logrank statistic. The first palpable tumor was used to calculate tumor latency for mice that developed either single or multiple mammary tumors. The time until necropsy was used for mice with occult tumors identified by microscopic examination. A two-sided Student's t test was used to calculate the differences in the number of tumors for each diet combination. Correlations between latency and treatment and/or diet were tested using a Cox proportional hazards model.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Modification of Mammary Tumorigenesis by Dietary Factors in Placebo-Treated Mice. We first evaluated the effects of dietary soy meal as compared with diets enriched with similar or lower doses of supplemental genistein and daidzein and with a control nonestrogenic casein diet on placebo-treated, wt-erbB-2 transgenic mice. Mice maintained on the soy meal diet (Purina 5001) experienced the longest mean tumor latency (mean, 39.8 weeks) and the lowest incidence of mammary tumor development by 60 weeks of age (67%; data shown in Fig. 1A and summarized in Table 3). Ninety-three percent of mice fed the high-dose, genistein and daidzein enriched diet (with the same estrogenic activity as the soy meal diet) developed mammary tumors by 60 weeks with a mean tumor latency of 37.3 weeks. All mice fed the low-dose isoflavone enriched diet developed mammary tumors by 60 weeks with a mean tumor latency of 39.5 weeks. All mice fed the nonestrogenic casein control diet also developed mammary tumors with a mean latency of 38.2 weeks. Statistical analysis by dietary groups indicates that the differences in mean latency are insignificant.



View larger version (14K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 1. Mammary tumor development in MMTV-wt-erbB-2 transgenic mice by diet. Red circles, casein; blue squares, low-dose isolated isoflavones; green diamonds, high-dose isolated isoflavones; orange triangles, soy meal diet. A, virgin transgenic mice were implanted with a placebo pellet at 8 weeks and maintained in a virgin state with the same dietary formula for life. B, transgenic mice implanted with a single 60-day release, 5 mg tamoxifen pellet in the lateral neck at 8 weeks of age. Mice were maintained as virgins on the diet indicated for life.

 

View this table:
[in this window]
[in a new window]

  		Table 3. Tumor development and latency by diet and treatment

 
Dietary Interactions with Tamoxifen-Associated Tumor Prevention. We next studied mice treated with continuous tamoxifen (8-16 weeks of age) to determine if interactions between dietary phytoestrogens and tumor prevention would be observed. For all tamoxifen-treated mice (n = 203), tumor development was significantly less than the control (P < 0.0001) or E2-treated mice (previously reported but shown in Table 3 for comparison; ref. 24). For the tamoxifen-treated mice that developed tumors, the mean tumor latency was significantly longer (42 weeks) than the placebo-treated animals (38.3 weeks); P < 0.0001 by ANOVA and Kruskal-Wallis tests.

Of particular importance, tamoxifen-associated mammary tumor prevention was also significantly reduced (to 46.8%) in mice fed the low isoflavone enriched diet as compared with all other diets (87.5% for the casein-fed, 83.7% for the soy meal-fed, and 83.5% for the high-dose isoflavone–fed mice; P = 0.0001). These differences can be visualized in a tabular form (Table 3). Despite this modification of tumor prevention by diet, significant differences in the mean tumor-free latency by diet were not observed. For example, in the tamoxifen-treated mice that developed mammary tumors, those maintained on a low-dose isoflavone diet had the shortest tumor-free interval (mean, 39.6 weeks) as compared with soy meal-fed (mean, 40 weeks), casein-fed (mean, 44.7 weeks), and high-dose isoflavone–fed mice (mean, 47.8 weeks; variances between these means are not significantly different). These data show that low-dose isoflavone abrogates tamoxifen-associated mammary tumor prevention in MMTV-wt-erbB-2/neu transgenic mice.

In vitro Studies of Isoflavone: Tamoxifen Interactions in Mammary Tumor Cell Lines. The protein expression levels of ß-actin, of ER isoforms {alpha} and ß, and of erbB-2 in five mammary tumor cell lines derived from the same transgenic mice and the human breast cancer cell line MCF-7 cell line are shown (Fig. 2A). All mouse mammary tumor lines were negative for ER{alpha}, positive for ERß, and had highlevels of erbB-2. This is in contrast to MCF-7, which was positive for both ER{alpha} and ERß and had a very low level of erbB-2. Our data are consistent with a general observation of inverse correlation between the ER{alpha} status and the expression levels of the epithelial growth factor receptor family members, including epidermal growth factor receptor and erbB-2 (29). Interestingly, a negative correlation between ER{alpha} and ERß expressions has also been reported (30). To further confirm the negativity of ER{alpha} in the novel mammary tumor-derived cell lines and to investigate if no expression of ER{alpha} is attributed to transcriptional or translational regulation, reverse transcription-PCR analyses were done. The specific ER{alpha} signal was only seen in the 15-week mouse mammary benign tissue, which is in agreement with our observation using immunostaining (data not shown), but not in the tumor-derived cell lines (Fig. 2B), suggesting that no expression of ER{alpha} in the erbB-2-overexpressing tumor–derived cell lines was regulated at the transcriptional level. CellTiter 96® Aqueous Non-Radioactive Cell Proliferation Assay Kit was then used to test the effects of tamoxifen and/or genistein by dose on the mammary tumor cell growth of these lines grown in an estrogen-free media (Fig. 2C). When these cells were exposed to tamoxifen alone, cell growth was inhibited in all five cell lines. With tamoxifen plus low doses of genistein (0.1 to 0.3 µmol/L), growth stimulation occurred in four of five cell lines. When higher concentrations of genistein were added to tamoxifen, growth inhibition occurred in all five cell lines. This inhibition was greater than that observed with tamoxifen alone, suggesting that the combination of tamoxifen and higher doses of genistein was synergistic in its ability to inhibit tumor cell growth.



View larger version (32K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 2. A, Western blot analyses of erbB-2/neu, ER{alpha}, ERß, and ß-actin proteins expressed by human and mouse mammary. Equal amounts of total cell lysates from each sample were used for Western blot analyses with antibodies directed against erbB-2/neu (c-neu Ab-3, Oncogene Research Products, San Diego, CA); ER{alpha} (62A3, monoclonal antibody, Cell Signaling Technology, Beverly, MA); ERß (rabbit polyclonal Ab; Upstate Cell Signaling Solutions, Lake Placid, NY); and ß-actin (clone AC-74, monoclonal antibody; Sigma Chemical). B, reverse transcription-PCR analyses of ER{alpha}. Total RNA was isolated from the indicated tumor cells and mouse mammary benign tissue (MBT) by the TRIZOL reagent. First-strand cDNA was synthesized using a kit from Roche. The partial coding sequence of ER{alpha} was amplified with specific primers. The PCR products were separated on a 2% agarose gel containing ethidium bromide and visualized under UV light. C, low dose of genistein abrogates the inhibitory effect of tamoxifen on mouse mammary tumor cell lines. The indicated mammary tumor cells (1.0 x 104) in 0.1 mL culture medium were plated onto 96-well plates. Twenty-four hours later, cells were grown in 0.1 mL of fresh DMEM/F12 (1:1) medium with 1% charcoal-stripped fetal bovine serum as control, or 0.1 mL of same medium containing 1 µmol/L tamoxifen, or 0.1 mL of same medium containing the same concentration of tamoxifen plus different doses of genistein. Cells were incubated at 37°C in a 5% CO2 atmosphere for 72 hours, and the percentage of cells surviving from each groups relative to controls, defined as 100% survival, was determined by reduction of MTS using the CellTiter96TM AQ nonradioactive cell proliferation assay kit. Data reflect the means of at least three independent experiments. SDs for each point were less than 10%.

 
A similar but more detailed experiment was carried out using the human breast cancer cell MCF-7. Any combination of genistein and tamoxifen at lower concentrations (<30 µmol/L for genistein and <10 µmol/L for tamoxifen) resulted in cell proliferation in vitro. If the concentrations of either agent were increased, growth inhibition was observed (Fig. 3A and B). Thus, the biphasic interactions between the different doses of genistein and tamoxifen were observed in both human and mouse mammary tumor cells, similar to our in vivo data using the transgenic mouse model.



View larger version (37K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 3. Effects of the interactions between tamoxifen and genistein on MCF-7 human breast cancer cell proliferation. MCF-7 cells (4.0 x 103) in 0.1 mL culture medium were plated onto 96-well plates. Twenty-four hours later, cells were grown in 0.1 mL fresh medium as control, or 0.1 mL fresh medium containing either tamoxifen or genistein alone, or 0.1 mL fresh medium containing different doses of tamoxifen and genistein. Same MTS assays were done as in Fig. 2C. A, G0, no genistein; G2, genistein 2 µmol/L; G10, genistein 10 µmol/L; G50, genistein 50 µmol/L. B, T0, no tamoxifen; T1, tamoxifen 1 µmol/L; T3, tamoxifen 3 µmol/L; T10, tamoxifen 10 µmol/L.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
The effects of isoflavones on cancer development have been studied in two chemically induced models of mammary carcinogenesis. In both the 7,12-dimethylbenz(a)anthracene-induced Sprague-Dawley and N-nitrosomethylurea-treated CD/Crj rat models, dietary isoflavones (either as a single factor or in combination with tamoxifen) produced beneficial antitumor affects (31–33). In rats with fully developed, palpable mammary tumors, the combination of tamoxifen and dietary soy reduced tumor growth (34). In contrast, however, several notable reports have raised concerns about possible deleterious effects of these agents in combination (21, 35, 36). Interactions between tamoxifen and the soy-based diet have also been reported using a combination of tamoxifen and genistein, given to nude mice bearing MCF-7 xenografts (37).

The MMTV-wt-erbB-2 transgenic mouse is a widely utilized model of mammary tumorigenesis (38). Increasing evidence suggests that both hormonal factors and receptor tyrosine kinase signaling are critical to normal homeostasis and tumorigenesis in mammary gland (39). Our previously reported data (24) suggest that estrogenic signaling derived from either exogenous hormones or dietary sources (or abrogation thereof) may modify both ductal/lobular morphogenesis and tumorigenesis. Though we observed no differences in mammary tumorigenesis in tamoxifen-treated mice fed the soy meal or casein (control) diet, we were particularly disturbed by the interaction between tamoxifen and the low-dose isoflavone diet. Our data suggest an abrogation of the memory effects of tamoxifen, with a reduction in tamoxifen-associated tumor prevention and shortened tumor latency. Similar interactions with genistein by dose were also observed in both human and mouse mammary tumor cell lines.

Given the recognized biphasic activity of phytoestrogens on ER-positive mammary tumor cells (40), it should not be surprising that isoflavones may promote cell growth at lower doses. We were surprised, however, that tamoxifen was not able to overcome these growth-promoting effects in our model system. The molecular mechanism behind these interactions may be multifactorial. Some have postulated that the mechanism of isoflavone protection is early modulation of mammary gland differentiation (41). We have previously reported that for this transgenic model, 8 to 16 weeks of age are the most sensitive to estrogenic influences (24). Other reported mechanisms of soy-mediated or isoflavone-mediated antitumor effects include (1) modification of SERM activity, (2) inhibition of topoisomerase II, (3) inhibition of tyrosine kinase activity, (4) antioxidant activity, (5) induction of apoptosis, (6) induction of cell cycle arrest, and (7) inhibition of angiogenesis. Using the human breast cancer cell lines MCF-7 and MDA-MB-231, we have shown that cell proliferation is enhanced at low concentrations of genistein (5 to 10 µmol/L) in association with mitogen-activated protein kinase activation.3 Microarray-based studies of benign glands from tamoxifen-treated mice are currently in progress to explore other signaling systems that may be involved in this process.

Dietary soy (or supplemental phytoestrogens) has been the focus of interest of both patients and physicians because of its observed reductive effect on cardiovascular disease, breast cancer, and prostate cancer (12, 14, 15). The intake of soy and other sources rich in phytoestrogens, however, is geographically and culturally dependent. For example, the Japanese consumption of soy provides 20 to 35 mg/d of isoflavones, whereas the U.S. diet provides 1 to 3 mg/d (or approximately one tenth of the Japanese consumption; Kelly patent application no. PCT/AU93/000230; refs. 42, 43). In addition to dose and regularity of intake, other data strongly suggest that both the stage of life (or age) during which isoflavone is consumed and the form in which it is ingested may critically influence its biological effects (19, 20). An intake of even a modest amount (≤100 mg) of isoflavones has been shown to exert important biological effects in vivo (16). The significantly lower incidence of hormone-dependent (and post-menopausal) tumors in Asia and Eastern Europe, as compared with Western countries, has been widely attributed to dietary isoflavones (44). Japanese women typically present at an earlier disease stage and have less aggressive breast cancers when compared with the women of United States or Britain (33). In addition, Japanese women show a better overall breast cancer survival than any other ethnic group (45).

The intake of soy-rich foods or derived supplements containing soy protein isolates and/or soy protein concentrates has increased dramatically in United States in the last decade (46). (http://www.cfsan.fda.gov/~dms/fdsoypr.html). Breast cancer survivors and individuals who perceive they are at an increased risk of breast cancer, in particular, have shown significant interest in the consumption of soy products, natural herbs, and over-the-counter supplements as disease- or risk-modulating factors (16–18). Although the quantitative data regarding this use are limited, dietary modulation seems remarkably common in newly diagnosed breast cancer patients. In one study, the majority of patients surveyed reported that they changed their diets post-diagnosis (47). Modification of food choice by cancer survivors is typically motivated by the belief that certain foods may prevent cancer (48). In one analysis of women enrolled in a randomized clinical treatment trial, 81% reported dietary supplementation (49). The ‘healthy’ estrogenic properties of soy have also resulted in the use of soy supplementation as an alternative to hormonal replacement therapy. Despite the evidence that suggests widespread usage of soy and derived isoflavone products by women and particularly breast cancer patients, several investigators have raised concerns that soy products may have negative effects on human health and, in fact, may promote breast carcinogenesis (16, 50).

These studies indicate that transgenic model systems may be readily amenable to studies of dietary factors, and interactions between diet, tumor formation, and other treatments. In particular, these models provide an opportunity to study the molecular and temporal sequence of tumorigenesis. We have also shown that the interactions we observed in the transgenic model can be recapitulated in both mouse and human cell lines. There have been no human studies to determine if soy/phytoestrogen consumption, or the dose of consumed products or supplements, may modify the preventive or treatment effects of tamoxifen. Our data raise the suspicion that low-dose phytoestrogens may interfere with the prevention or treatment benefits of tamoxifen.

We found that a low-dose isoflavone enriched diet abrogated tamoxifen-associated mammary tumor prevention. Using both human and mouse mammary tumor cell lines, we confirmed that low-dose genistein reversed the growth-inhibitory effects of tamoxifen. These results provide important insights into possible modulating factors that may influence the efficacy of SERMs for breast cancer prevention or treatment. Whereas we acknowledge that mouse studies may not be directly translatable to the intake of variable or intermittent phytoestrogens by humans, our data raise the concern that deleterious interactions between phytoestrogens and tamoxifen may occur. Given the clinical relevance of this observation, we hope that clinical trials will be designed to explore these interactions. At the very least, physicians and patients should be made aware of these possible interactions and data should be accrued prospectively. It seems likely that many of the over-the-counter diet supplements have biological effects and may interact with prescribed drugs and patient outcomes.


   Acknowledgments
 
Grant support: NIH grants 1RO1 CA82848 and 1P50 CA89018.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   Footnotes
 
3 X. Yang and A. Thor, unpublished data. Back

Received 6/ 1/04. Revised 11/10/04. Accepted 11/19/04.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Fishman J, Osborne MP, Telang NT. The role of estrogen in mammary carcinogenesis. Ann N Y Acad Sci 1995;768:91–100.[Medline]
  2. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative. I. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial [see comment]. JAMA 2002;288:321–33.[Abstract/Free Full Text]
  3. Grabrick DM, Hartmann LC, Cerhan JR, et al. Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer see comment. JAMA 2000;284:1791–8.[Abstract/Free Full Text]
  4. Come SE, Buzdar AU, Arteaga CL, et al. Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement. Clin Cancer Res 2003;9:443–6S.
  5. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell 1995;83:835–9.[CrossRef][Medline]
  6. Knowlden JM, Gee JM, Robertson JF, Ellis IO, Nicholson RI. A possible divergent role for the oestrogen receptor {alpha} and ß subtypes in clinical breast cancer. Int J Cancer 2000;89:209–12.[CrossRef][Medline]
  7. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators—mechanisms of action and application to clinical practice [see comment]. N Engl J Med 2003;348:618–29.[Free Full Text]
  8. Jensen EV, Jordan VC. The estrogen receptor: a model for molecular medicine. Clin Cancer Res 2003;9:1980–9.[Abstract/Free Full Text]
  9. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study [see comment]. J Natl Cancer Inst 1998;90:1371–88.[Abstract/Free Full Text]
  10. Schiff R, Massarweh S, Shou J, Osborne CK. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res 2003;9:447–54S.
  11. Price KR, Fenwick GR. Naturally occurring oestrogens in foods—a review. Food Addit Contam 1985;2:73–106.[Medline]
  12. Brownson DM, Azios NG, Fuqua BK, Dharmawardhane SF, Mabry TJ. Flavonoid effects relevant to cancer. J Nutr 2002;132:3482–9S.
  13. Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs [see comment]. Science 2002;295:2465–8.[Abstract/Free Full Text]
  14. Henkel J. Soy. Health claims for soy protein, questions about other components. FDA Consum 2000;34:13–5;18–20.
  15. Ross JA, Kasum CM. Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu Rev Nutr 2002;22:19–34.[CrossRef][Medline]
  16. Messina MJ, Loprinzi CL. Soy for breast cancer survivors: a critical review of the literature. J Nutr 2001;131:3095–108S.
  17. Messina M, Barnes S. The role of soy products in reducing risk of cancer. J Natl Cancer Inst 1991;83:541–6.[Free Full Text]
  18. Eden JA, Wren BG. Hormone replacement therapy after breast cancer: a review. Cancer Treat Rev 1996;22:335–43.[CrossRef][Medline]
  19. Bouker KB, Hilakivi-Clarke L. Genistein: does it prevent or promote breast cancer? Environ Health Perspect 2000;108:701–8.
  20. Lee HP, Gourley L, Duffy SW, Esteve J, Lee J, Day NE. Dietary effects on breast-cancer risk in Singapore [see comment]. Lancet 1991;337:1197–200.[CrossRef][Medline]
  21. An J, Tzagarakis-Foster C, Scharschmidt TC, Lomri N, Leitman DC. Estrogen receptor ß-selective transcriptional activity and recruitment of coregulators by phytoestrogens. J Biol Chem 2001;276:17808–14.[Abstract/Free Full Text]
  22. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986;232:1644–6.[Abstract/Free Full Text]
  23. Pinkas-Kramarski R, Alroy I, Yarden Y. ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signaling. J Mammary Gland Biol Neoplasia 1997;2:97–107.[CrossRef][Medline]
  24. Yang X, Edgerton SM, Kosanke SD, et al. Hormonal and dietary modulation of mammary carcinogenesis in mouse mammary tumor virus-c-erbB-2 transgenic mice. Cancer Res 2003;63:2425–33.[Abstract/Free Full Text]
  25. Jeruss JS, Liu NX, Chung Y, et al. Characterization and chromosomal instability of novel derived cell lines from a wt-erbB-2 transgenic mouse model. Carcinogenesis 2003;24:659–64.[Abstract/Free Full Text]
  26. Kosanke SD, Edgerton SM, Moore DI, et al. Mammary tumor heterogeneity in wt-ErbB-2 transgenic mice. Comp Med 2004;54:268–75.
  27. Thigpen JE, Setchell KD, Ahlmark KB, et al. Phytoestrogen content of purified, open- and closed-formula laboratory animal diets. Lab Anim Sci 1999;49:530–6.[Medline]
  28. Liu B, Peng D, Lu Y, Jin W, Fan Z. A novel single amino acid deletion caspase-8 mutant in cancer cells that lost proapoptotic activity. J Biol Chem 2002;277:30159–64.[Abstract/Free Full Text]
  29. Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer [see comment]. J Natl Cancer Inst 2003;95:142–53.[Abstract/Free Full Text]
  30. Bieche I, Parfait B, Laurendeau I, Girault I, Vidaud M, Lidereau R. Quantification of estrogen receptor {alpha} and ß expression in sporadic breast cancer. Oncogene 2001;20:8109–15.[CrossRef][Medline]
  31. Lamartiniere CA, Moore JB, Brown NM, Thompson R, Hardin MJ, Barnes S. Genistein suppresses mammary cancer in rats. Carcinogenesis 1995;16:2833–40.[Abstract/Free Full Text]
  32. Constantinou AI, Lantvit D, Hawthorne M, Xu X, van Breemen RB, Pezzuto JM. Chemopreventive effects of soy protein and purified soy isoflavones on DMBA-induced mammary tumors in female Sprague-Dawley rats. Nutr Cancer 2001;41:75–81.[CrossRef][Medline]
  33. Barnes S, Grubbs C, Setchell KD, Carlson J. Soybeans inhibit mammary tumors in models of breast cancer. Prog Clin Biol Res 1990;347:239–53.[Medline]
  34. Gotoh T, Yamada K, Ito A, Yin H, Kataoka T, Dohi K. Chemoprevention of N-nitroso-N-methylurea-induced rat mammary cancer by miso and tamoxifen, alone and in combination. Jpn J Cancer Res 1998;89:487–95.[CrossRef][Medline]
  35. Allred CD, Allred KF, Ju YH, Virant SM, Helferich WG. Soy diets containing varying amounts of genistein stimulate growth of estrogen-dependent (MCF-7) tumors in a dose-dependent manner. Cancer Res 2001;61:5045–50.[Abstract/Free Full Text]
  36. Hsieh CY, Santell RC, Haslam SZ, Helferich WG. Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Res 1998;58:3833–8. Erratum in: Cancer Res 1999 Mar 15;59:1388.[Abstract/Free Full Text]
  37. Ju YH, Doerge DR, Allred KF, Allred CD, Helferich WG. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res 2002;62:2474–7.[Abstract/Free Full Text]
  38. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu proto-oncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 1992;89:10578–82.[Abstract/Free Full Text]
  39. Troyer KL, Lee DC. Regulation of mouse mammary gland development and tumorigenesis by the ERBB signaling network. J Mammary Gland Biol Neoplasia 2001;6:7–21.[CrossRef][Medline]
  40. Wang C, Kurzer MS. Phytoestrogen concentration determines effects on DNA synthesis in human breast cancer cells. Nutr Cancer 1997;28:236–47.[Medline]
  41. Lamartiniere CA, Cotroneo MS, Fritz WA, Wang J, Mentor-Marcel R, Elgavish A. Genistein chemoprevention: timing and mechanisms of action in murine mammary and prostate. J Nutr 2002;132:552–8S.
  42. Wu AH, Ziegler RG, Nomura AM, et al. Soy intake and risk of breast cancer in Asians and Asian Americans. Am J Clin Nutr 1998;68:1437–43S.
  43. Nagata C, Kabuto M, Kurisu Y, Shimizu H. Decreased serum estradiol concentration associated with high dietary intake of soy products in premenopausal Japanese women. Nutr Cancer 1997;29:228–33.[Medline]
  44. Yamamoto S, Sobue T, Kobayashi M, Sasaki S, Tsugane S; Japan Public Health Center-Based Prospective Study on Cancer Cardiovascular Diseases, G. Soy, isoflavones, and breast cancer risk in Japan [see comment]. J Natl Cancer Inst 2003;95:906–13.[Abstract/Free Full Text]
  45. Meng L, Maskarinec G, Wilkens L. Ethnic differences and factors related to breast cancer survival in Hawaii. Int J Epidemiol 1997;26:1151–8.[Abstract/Free Full Text]
  46. Morton MS, Wilcox G, Wahlqvist ML, Griffiths K. Determination of lignans and isoflavonoids in human female plasma following dietary supplementation. J Endocrinol 1994;142:251–9.[Abstract/Free Full Text]
  47. Thomson CA, Flatt SW, Rock CL, Ritenbaugh C, Newman V, Pierce JP. Increased fruit, vegetable and fiber intake and lower fat intake reported among women previously treated for invasive breast cancer. J Am Diet Assoc 2002;102:801–8.[CrossRef][Medline]
  48. Maskarinec G, Murphy S, Shumay DM, Kakai H. Dietary changes among cancer survivors. Eur J Cancer Care (Engl) 2001;10:12–20.
  49. Newman V, Rock CL, Faerber S, Flatt SW, Wright FA, Pierce JP. Dietary supplement use by women at risk for breast cancer recurrence. The Women's Healthy Eating and Living Study Group. J Am Diet Assoc 1998;98:285–92.[CrossRef][Medline]
  50. Emens LA, Davidson NE. Adjuvant hormonal therapy for premenopausal women with breast cancer. Clin Cancer Res 2003;9:486–94S.



This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
B. N. Fink, S. E. Steck, M. S. Wolff, J. A. Britton, G. C. Kabat, M. M. Gaudet, P. E. Abrahamson, P. Bell, J. C. Schroeder, S. L. Teitelbaum, et al.
Dietary Flavonoid Intake and Breast Cancer Survival among Women on Long Island
Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2285 - 2292.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
C. Duffy, K. Perez, and A. Partridge
Implications of Phytoestrogen Intake for Breast Cancer
CA Cancer J Clin, September 1, 2007; 57(5): 260 - 277.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. H. Wu, M. C. Pike, L. D. Williams, D. Spicer, C.-C. Tseng, M. I. Churchwell, and D. R. Doerge
Tamoxifen, Soy, and Lifestyle Factors in Asian American Women With Breast Cancer
J. Clin. Oncol., July 20, 2007; 25(21): 3024 - 3030.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. GenomicsHome page
Y. Su, F. A. Simmen, R. Xiao, and R. C. M. Simmen
Expression profiling of rat mammary epithelial cells reveals candidate signaling pathways in dietary protection from mammary tumors
Physiol Genomics, June 19, 2007; 30(1): 8 - 16.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
Z. Mai, G. L. Blackburn, and J.-R. Zhou
Soy phytochemicals synergistically enhance the preventive effect of tamoxifen on the growth of estrogen-dependent human breast carcinoma in mice
Carcinogenesis, June 1, 2007; 28(6): 1217 - 1223.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
S. Rice and S. A Whitehead
Phytoestrogens and breast cancer -promoters or protectors?
Endocr. Relat. Cancer, December 1, 2006; 13(4): 995 - 1015.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
J. O. Moore, Y. Wang, W. G. Stebbins, D. Gao, X. Zhou, R. Phelps, M. Lebwohl, and H. Wei
Photoprotective effect of isoflavone genistein on ultraviolet B-induced pyrimidine dimer formation and PCNA expression in human reconstituted skin and its implications in dermatology and prevention of cutaneous carcinogenesis
Carcinogenesis, August 1, 2006; 27(8): 1627 - 1635.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
C.-C. Lin, Y.-L. Tsai, M.-T. Huang, Y.-P. Lu, C.-T. Ho, S.-F. Tseng, and S.-C. Teng
Inhibition of estradiol-induced mammary proliferation by dibenzoylmethane through the E2-ER-ERE-dependent pathway
Carcinogenesis, January 1, 2006; 27(1): 131 - 136.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
P. Thelen, J.-G. Scharf, P. Burfeind, B. Hemmerlein, W. Wuttke, B. Spengler, V. Christoffel, R.-H. Ringert, and D. Seidlova-Wuttke
Tectorigenin and other phytochemicals extracted from leopard lily Belamcanda chinensis affect new and established targets for therapies in prostate cancer
Carcinogenesis, August 1, 2005; 26(8): 1360 - 1367.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
R. T. Chlebowski and G. L. Anderson
Progestins and Recurrence in Breast Cancer Survivors
J Natl Cancer Inst, April 6, 2005; 97(7): 471 - 472.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, B.
Right arrow Articles by Thor, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, B.
Right arrow Articles by Thor, A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online